A healthy world made by
diagnosis and prediction

D&P Biotech Co., Ltd. was founded in March 2006 with a vision of Diagnosis & Prediction
for disease detection and prognosis, driven by Dream & Passion to create value from our research outcomes.

Scroll Down

Slogans

A step towards
a healthy life

Full-service
R&D solutions

A healthy world through
diagnosis and prediction

Subscribe

contact

Healthy bebe

Healthy bebeTM Vaginal 5 Species Quantification Reagent (100 Test)

  • Predicting the risk of Preterm birth

  • Accurate Algorithm developed using decision tree

  • Screening of high-risk mothers using qPCR analysis

Key Features

  • Fast Turnaround Time

    Real-time PCR: 90 minutes.

  • Contamination Prevention

    UDG system

  • Whole Process Control

    Monitoring throughout the experiment

  • Automated Analysis

    High/Moderate/Low Risk

  • Preterm birth, defined as delivery before 37 weeks of gestation, accounts for nearly 70% of neonatal deaths worldwide. With declining birth rates, prenatal care from conception through birth is more critical than ever.

  • Microbial infections in the amniotic fluid, blood, and vagina can trigger complications such as premature rupture of membranes (PPROM), cervical inflammatory response, microbial invasion of the amniotic sac (MIAC), and intra-amniotic infection (IAI)—all of which significantly increase preterm birth risk.

  • The Healthy bebeTM Vaginal 5 Species Quantitative Reagent (Product #: PB7500-100T) analyzes five microorganisms in the mother’s vaginal microbiome, aiding in predicting preterm birth risk and facilitating appropriate treatment and care.

  • Analytical Device

    • AB7500 (Applied Biosystem)

  • Clinical Sample

    • Cervical Fluid (& swab)

  • Analyze Microorganisms

    • Lactobacillus crispatus (L.C)

    • Lactobacillus iners (L.I)

    • Ureaplasma urealyticum (U.U)

    • Ureaplasma parvum (U.P)

    • Gardnerella vaginalis (G.V)

Results of clnical Evaluation

Results of clnical Evaluation
Algorithm Sensitivity Specificity Positive Predictive
value		 Negative Predictive
value		 AUC
Algorithm 11 89.4% 40.1% 59.2% 80.6% 74.3%
Algorithm 22 65.2% 68.9% 67.3% 67.0% 71.5%
Algorithm 23 77.9% 57.0% 65.8% 77.5% 77.3%

1) & 2) Analysis algorithm based on microbial quantification and distribution

3) Algorithm based on microbial quantification and BMI/WBC values

Brochure

Lung Cancer

Eight Genes SNP Multiplex Genotyping Kit (48test)

  • Predicting patients with high risk of lung cancer recurrence

  • Simultaneous testing for SNPs in 8 lung cancer-related genes

Key Features

  • Fast Turnaround Time

    Real-time PCR results: 80 minutes.

  • Patient Specific

    Designed for patients who have undergone surgery for early-stage non-small cell lung cancer.

  • Risk Interpretation

    high/low risk

  • Qualitative Analysis

    Analyzes eight SNPs

  • Despite advancements in lung cancer diagnosis and treatment, the five-year survival rate remains around 20%, making it a leading cause of cancer-related deaths.

  • This genetic analysis kit enables multi-marker detection through real-time polymerase chain reaction (PCR) to predict postoperative prognosis in early-stage non-small cell lung cancer. It utilizes eight biomarkers identified through patented research and published studies.

  • The kit provides molecular biological insights into a patient’s prognostic risk, assisting clinicians in personalizing treatment strategies for their patients.

  • Analytical Device

    • AB7500 (Applied Biosystem)

  • Clinical Sample

    • Whole Blood

  • Analyze Microorganisms

    • ADAMTSL3

      CD3EAP

    • AKT1

      GNB2L1

    • C3

      HOMER2

    • CD3D

      TNFRSF10B

Results of clnical Evaluation

Results of clnical Evaluation
Clinical
performance
Evaluation		 Sensitivity Specificity Positive Predictive
value		 Negative Predictive
value		 AUC
(%) 21.2 90.9 48.6 73.9 70.7
Video
Brochure